GLP-1 drugs are seen as the next top-selling chronic disease treatment, with the potential to transform care the same way cholesterol-lowering statins did for patients at high risk of heart disease more than 30 years ago. The commercial potential is propelling drugmakers like Novo and Lilly to the top of the US and European markets. Investors are also eyeing Pfizer Inc.’s experimental danuglipron after a mid-stage study yielded positive results.
node: "uvc_camera",
。有道翻译官网对此有专业解读
When they announced its relaunch, Rose told The Verge that AI could "remove the janitorial work of moderators and community managers." Now, the new Digg's CEO Justin Mezzell writes in a note pinned to the homepage that, "We knew bots were …
FT Digital Edition: our digitised print edition